Evidence map›Paper›PMID 26468015›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

ROS-mediated activation of JNK/p38 contributes partially to the pro-apoptotic effect of ajoene on cells of lung adenocarcinoma.

Yingyi Wang, Zhao Sun, Shuchang Chen, Yuchen Jiao, Chunmei Bai

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Pathophysiological Role of Vimentin Intermediate Filaments in Lung Diseases.Frontiers in cell and developmental biology · 2022
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Garlic oil polysulfides: H2S- and O2-independent prooxidants in buffer and antioxidants in cells.American journal of physiology. Regulatory, integrative and comparative physiology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yingyi WangOncology Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, NO. 1, ShuaiFuYuan Hutong, Dongcheng District, Beijing, 100730, People's Republic of China.
Zhao SunOncology Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, NO. 1, ShuaiFuYuan Hutong, Dongcheng District, Beijing, 100730, People's Republic of China.
Shuchang ChenOncology Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, NO. 1, ShuaiFuYuan Hutong, Dongcheng District, Beijing, 100730, People's Republic of China.
Yuchen JiaoLaboratory of Cell and Molecular Biology and State Key Laboratory of Molecular Oncology, Cancer Institute & Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, 100021, People's Republic of China.
Chunmei BaiOncology Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, NO. 1, ShuaiFuYuan Hutong, Dongcheng District, Beijing, 100730, People's Republic of China. baichunmei2001@163.com.
Peking Union Medical College Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ajoene, a garlic-derived organosulfur compound, exerts anti-tumorigenic effect against various cancers. However, little is known about the biological effect of ajoene on lung adenocarcinoma, an aggressive malignancy with dismal prognosis. We investigated the biological effect of ajoene on lung adenocarcinoma and the underlying pathway. Lung adenocarcinoma cells A549, NCI-H1373, and NCI-H1395, along with the noncancerous lung bronchus cells BEAS-2B, were used. MTT test showed that ajoene (25 μM) reduces viability of lung adenocarcinoma cells but not the noncancerous BEAS-2B cells. Bromodeoxyuridine incorporation assay revealed that ajoene inhibits proliferation of lung adenocarcinoma cells. Treatment of lung adenocarcinoma cells with ajoene enhances apoptosis and ROS generation in a time- and dose-dependent fashion. Abrogation of caspase activation by zVAD-fmk completely prevents the ajoene-induced apoptosis; whereas block of ROS generation by N-acetylcysteine partly abolishes the ajoene-induced apoptosis. ROS-mediated induction of apoptosis contributes partially to the anti-tumorigenic property of ajoene observed, a phenomenon also confirmed by xenograft tumor study. Mitogen activated protein kinases (MAPKs), pivots of ROS-mediated signaling pathway, are activated upon ajoene treatment; Jun-N-terminal kinase (JNK)/p38 activations are required for signaling pathway underlying the ajoene-induced apoptosis. Our results suggest that ROS-mediated activation of JNK/p38 contributes partially to the pro-apoptotic action of ajoene on cells of lung adenocarcinoma. Ajoene may be a promising chemotherapeutic agent for lung adenocarcinoma.

Indexed as

A549 CellsAdenocarcinomaAmino Acid Chloromethyl KetonesAnimalsApoptosisCaspase InhibitorsCaspasesCell LineCell Line, TumorCell SurvivalDisulfidesDose-Response Relationship, DrugEnzyme ActivationEnzyme InhibitorsHumansImmunoblottingajoeneAmino Acid Chloromethyl Ketonesbenzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneCaspase InhibitorsCaspasesDisulfidesEnzyme InhibitorsJNK Mitogen-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesReactive Oxygen SpeciesSulfoxidesAdenocarcinomaAjoeneApoptosisLungMAPKsROS

Identifiers

PMID26468015
OpenAlexW2179158483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.